IFNA2 and hepatocellular carcinoma: A systematic review of thirteen randomized control trials indicated that the beneficial effects of adjuvant IFN-α therapy reduced the rate of recurrence and IFN-α did not appear to improve the survival of HCV-associated HCC patients following curative therapy (73).